Royal Philips, parent company of Philips Healthcare, announced that the first patient has been enrolled in the WE-TRUST study in Spain to assess whether its enhanced workflow system can improve outcomes in patients after stroke onset.
The multicenter, randomized clinical trial will test the impact of the company's Direct to Angio Suite workflow system in 564 patients at 15 sites. The trial will analyze whether combining diagnosis and treatment of stroke patients in the angio suite improves outcomes over conventional workflows, wherein diagnosis is performed in a CT or MRI suite followed by treatment in an angio suite.
The primary endpoint of the WE-TRUST trial is clinical outcome measured by patients' functional status (mRS) three months after the procedure, the company said. The trial will primarily be carried out on Philips' image-guided therapy system, Azurion.
WE-TRUST is an acronym for the trial's description: "Workflow optimization to reduce time to endovascular reperfusion for ultrafast stroke treatment."
In other announcements, Philips said it has entered a strategic partnership with Dutch medical technology company Nico.Lab, which received U.S. Food and Drug Administration clearance last year for its StrokeViewer LVO, an artificial intelligence algorithm that detects image characteristics associated with a large vessel occlusion.
